Allied Biotech Corporation

Total Valuation

Allied Biotech Corporation carries a market capitalization of 2.41B, placing it among publicly traded companies globally. Its enterprise value stands at 2.11B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Allied Biotech Corporation currently has 96.24M shares outstanding.

Valuation Ratios

Allied Biotech Corporation trades at a trailing price-to-earnings ratio of 17.20. The price-to-sales ratio is 2.62, and the price-to-book ratio stands at 1.97.

Enterprise Valuation

On an enterprise value basis, Allied Biotech Corporation trades at an EV/EBITDA multiple of 17.49 and an EV/FCF ratio of 7.97. The EV/Sales ratio of 2.48 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 17.49 provides insight into valuation relative to core operating earnings.

Financial Position

Allied Biotech Corporation maintains a current ratio of 1.90, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 59.41, indicating elevated leverage, while an interest coverage ratio of 6.95 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Allied Biotech Corporation posts a return on equity of 11.57 and a return on invested capital of 4.58.

Taxes

Over the trailing twelve months, Allied Biotech Corporation has paid 34.67M in income taxes, reflecting an effective tax rate of 21.12.

Stock Price Statistics

Allied Biotech Corporation's stock has gained approximately 29.87013% over the past 52 weeks. The 50-day moving average sits at 30.06, while the 200-day moving average is 24.71.

Income Statement

Over the trailing twelve months, Allied Biotech Corporation generated 849.51M in revenue and converted that into 129.46M in net income, yielding earnings per share of 1.34. EBITDA reached 120.39M, while operating income came in at 120.39M.

Balance Sheet

Allied Biotech Corporation holds 853.91M in cash and equivalents against 733.53M in total debt, resulting in a net debt position of -64.70M. Total book value stands at 1.13B, with working capital of 721.44M providing operational flexibility.

Cash Flow

Allied Biotech Corporation produced 217.13M in operating cash flow over the past twelve months. After subtracting -33.58M in capital expenditures, free cash flow totaled 183.55M - equivalent to 1.90 per share.

Margins

Allied Biotech Corporation operates with a gross margin of 36.33, reflecting its pricing power and cost economics. The operating margin of 14.17 and net profit margin of 15.24 provide insight into operational efficiency.

Dividends & Yields

Scores

Allied Biotech Corporation posts an Altman Z-Score of 2.68, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.